achieve life sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.
Company profile
Ticker
ACHV
Exchange
Website
CEO
Richard Stewart
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Achieve Life Sciences Technologies Inc., incorporated • Achieve Life Science Inc. • Extab Corporation • Achieve Pharma UK Limited, a Limited Company ...
IRS number
954343413
ACHV stock data
Latest filings (excl ownership)
8-K
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
29 Feb 24
424B5
Prospectus supplement for primary offering
29 Feb 24
8-K
Other Events
11 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update
9 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update
14 Aug 23
EFFECT
Notice of effectiveness
26 Jun 23
CORRESP
Correspondence with SEC
21 Jun 23
UPLOAD
Letter from SEC
20 Jun 23
Transcripts
ACHV
Earnings call transcript
2023 Q3
9 Nov 23
ACHV
Earnings call transcript
2023 Q2
15 Aug 23
ACHV
Earnings call transcript
2023 Q1
9 May 23
ACHV
Earnings call transcript
2022 Q4
16 Mar 23
ACHV
Earnings call transcript
2022 Q3
14 Nov 22
ACHV
Earnings call transcript
2022 Q2
12 Aug 22
ACHV
Earnings call transcript
2022 Q1
13 May 22
ACHV
Earnings call transcript
2021 Q4
10 Mar 22
ACHV
Earnings call transcript
2021 Q3
10 Nov 21
ACHV
Earnings call transcript
2021 Q2
13 Aug 21
Latest ownership filings
SC 13G
FRANKLIN RESOURCES INC
11 Mar 24
4
Richard Alistair Stewart
6 Mar 24
4
John Bencich
6 Mar 24
SC 13G
Callahan Patrick J. III
27 Feb 24
4
Bridget A Martell
29 Jan 24
4
THOMAS BRAXTON KING
24 Jan 24
4
Stuart Duty
24 Jan 24
4
Thomas Sellig
24 Jan 24
4
VAUGHN B HIMES
24 Jan 24
4
Jerry Wan
24 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.97 mm | 19.97 mm | 19.97 mm | 19.97 mm | 19.97 mm | 19.97 mm |
Cash burn (monthly) | 1.72 mm | (no burn) | 4.42 mm | 5.66 mm | 1.71 mm | 2.60 mm |
Cash used (since last report) | 10.22 mm | n/a | 26.31 mm | 33.69 mm | 10.19 mm | 15.49 mm |
Cash remaining | 9.75 mm | n/a | -6.34 mm | -13.72 mm | 9.78 mm | 4.47 mm |
Runway (months of cash) | 5.7 | n/a | -1.4 | -2.4 | 5.7 | 1.7 |
Institutional ownership, Q2 2023
33.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 45 |
Opened positions | 12 |
Closed positions | 4 |
Increased positions | 15 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 17.08 bn |
Total shares | 11.33 mm |
Total puts | 41.10 k |
Total calls | 151.60 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Dialectic Capital Management | 3.54 mm | $0.00 |
Contrarian Alpha | 1.98 mm | $11.18 mm |
Contrarian Achieve SPV | 1.32 mm | $3.15 mm |
Shay Capital | 776.60 k | $4.03 bn |
Vanguard | 577.79 k | $3.00 bn |
Francis Capital Management | 560.10 k | $0.00 |
AWM Investment | 272.50 k | $1.41 bn |
Packer Paul | 253.63 k | $2.05 mm |
Long Focus Capital Management | 248.10 k | $1.29 bn |
CVI Investments | 227.12 k | $1.84 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Stewart Richard Alistair | Common Stock | Buy | Acquire P | No | No | 4.585 | 10,000 | 45.85 k | 38,501 |
4 Mar 24 | Stewart Richard Alistair | Common Stock Warrants Common Stock | Buy | Acquire P | No | No | 4.906 | 10,000 | 49.06 k | 10,000 |
4 Mar 24 | John Bencich | Common Stock | Buy | Acquire P | No | No | 4.585 | 10,000 | 45.85 k | 76,724 |
4 Mar 24 | John Bencich | Common Stock Warrants Common Stock | Buy | Acquire P | No | No | 4.906 | 10,000 | 49.06 k | 10,000 |
22 Jan 24 | John Bencich | Stock Option Common Stock | Grant | Acquire A | No | No | 4.55 | 75,000 | 341.25 k | 75,000 |
22 Jan 24 | John Bencich | RSU Common Stock | Grant | Acquire A | No | No | 0 | 175,000 | 0.00 | 175,000 |
22 Jan 24 | Cindy Jacobs | Stock Option Common Stock | Grant | Acquire A | No | No | 4.55 | 36,000 | 163.80 k | 36,000 |
22 Jan 24 | Cindy Jacobs | RSU Common Stock | Grant | Acquire A | No | No | 0 | 84,000 | 0.00 | 84,000 |
22 Jan 24 | Stewart Richard Alistair | Stock Option Common Stock | Grant | Acquire A | No | No | 4.55 | 60,000 | 273.00 k | 60,000 |
22 Jan 24 | Stewart Richard Alistair | RSU Common Stock | Grant | Acquire A | No | No | 0 | 140,000 | 0.00 | 140,000 |
Press releases
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
20 Mar 24
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
29 Feb 24